Du är här


Novartis International AG: Novartis settles patent litigation on Gleevec® (imatinib mesylate) with Sun Pharma subsidiary

Novartis International AG / Novartis settles patent litigation on Gleevec®
(imatinib mesylate) with SunPharma subsidiary . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
* Litigation settlement upholds validity of US patents covering polymorphic
forms of Gleevec and permits Sun Pharma subsidiary to launch a generic
version on February 1, 2016
* Patents are vital to the ability of innovative companies like Novartis to
invest in high-risk research to advance breakthrough treatments for

Basel, Switzerland, May 15, 2014
-- Novartis Pharmaceuticals Corporation has settled its litigation with the
United States subsidiary of Sun Pharmaceutical Industries Ltd. relating to
Novartis patents covering the use of certain polymorphic forms of
Gleevec®(imatinib mesylate), which expire in 2019 (including pediatric
exclusivity). The basic compound patent for Gleevec expires in the U.S. on
July 4, 2015.

As a result of the settlement, Novartis will permit Sun Pharma's subsidiary to
market a generic version of Gleevec in the United States on February 1, 2016.
The terms of the settlement agreement are otherwise confidential. Sun
Pharma's subsidiary has received tentative approval from the US Food and Drug
Administration (FDA) for its generic version of imatinib mesylate.

Patents are vital to the ability of innovative companies like Novartis to
invest in high-risk research to advance breakthrough treatments for patients
without treatment options. This settlement validates the Novartis patents
while allowing Sun Pharma's subsidiary to enter the market with its generic

Novartis is the first healthcare company with a global leadership position in
both patented prescription and generic pharmaceuticals. Offering high-quality
generics through its Sandoz division plays a critical role in the Novartis
strategy of offering a complete range of treatment options to patients,
physicians and healthcare providers worldwide.

The foregoing release contains forward-looking statements that can be
identified by words such as "permits," "to launch," "expire," "will,"
"tentative," "to enter," "strategy," or similar terms, or by express or
implied discussions regarding potential future revenues from Gleevec. You
should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown
risks and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Gleevec will be commercially successful in the
future. In particular, management's expectations regarding Gleevec could be
affected by, among other things, the company's ability to obtain or maintain
proprietary intellectual property protection; general economic and industry
conditions; global trends toward health care cost containment, including
ongoing pricing pressures; unexpected regulatory actions or delays or
government regulation generally; unexpected manufacturing issues; the
uncertainties inherent in research and development, including unexpected
clinical trial results and additional analysis of existing clinical data, and
other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing
the information in this press release as of this date and does not undertake
any obligation to update any forward-looking statements contained in this
press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals, preventive
vaccines, over-the-counter and animal health products. Novartis is the only
global company with leading positions in these areas. In 2013, the Group
achieved net sales of USD 57.9 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 135,000 full-time-equivalent associates and sell products in
more than 150 countries around the world. For more information, please

Novartis is on Twitter. Sign up to follow @Novartis

# # #

Novartis Media Relations

|Central media line : |
|+41 61 324 2200 |
|Eric Althoff Geoffrey Cook |
| |
| |
|Novartis Global Media Relations Novartis Oncology Communications |
| +1 862 778 2675 |
| +1 973 652 7927 |
|+41 61 324 7999 (direct) geoffrey.cook@novartis.com |
| |
|+41 79 593 4202 (mobile) |
|eric.althoff@novartis.com |

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis

For questions about the site or required registration, please

Novartis Investor Relations

|Central phone: +41 61 324 7944 |
|Samir Shah +41 61 324 7944 North America: |
|Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 |
|Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257 |
|Isabella Zinck +41 61 324 7188 |
| |
|e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
| |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.